Current status and recent developments in molecular targeted therapy against gastric cancer

World Chinese Journal of Digestology

Volumn 15, Issue 25, 2007, Pages 2672-2678

  Lv, Wei ^a   Chen, Lin ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Gastric cancer; Molecular targeted therapy

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; IMATINIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PERTUZUMAB; SEMAXANIB; TRASTUZUMAB; VANDETANIB;

ANGIOGENESIS; APOPTOSIS; CANCER ADJUVANT THERAPY; CELL CYCLE; CELL GROWTH; CHINA; HUMAN; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; REVIEW; STOMACH CANCER;

EID: 36849020941     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Shah MA, Schwartz GK. Treatment of metastatic esophagus and gastric cancer. Semin Oncol 2004; 31: 574-587
2. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167
3. Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De Falco A, Nanayakkara M, Bottero D, De Stasio R, Varricchio L, Auricchio F. Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 2006; 1089: 194-200
4. Scaltriti M, Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 2006; 12: 5268-5272
5. Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 2006; 12: 3297-3305
6. Arnold D, Peinert S, Voigt W, Schmoll HJ. Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist 2006; 11: 602-611
7. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, Skliris GP, Murphy LC, Los M. Targeting the EGFR pathway for cancer therapy. Curr Med Chem 2006; 13: 3483-3492
8. Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 2006; 6: 691-710
9. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002; 29: 3-9
10. Krozely P. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors. Clin J Oncol Nurs 2004; 8: 163-168
11. Doi T, Koizumi W, Siena S, S. Cascinu, A. Ohtsu, M. Michael, H. Takiuchi, H. Swaisland, N. Gallagher, E. Van Cutsem. Efficacy, tolerability and pharmacokinetics of gefitinib (ZD1839) in pretreated patients with metastatic gastric cancer. Proc Am Soc Clin Oncol 2003; 22: abstr 1036
12. Adelstein DJ, Rybicki LA, Carroll MA, T. W. Rice, T. Mekhail. Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GeJ) cancer. Proc Am Soc Clin Oncol 2005; 23(16 suppl): 4054a
13. Rojo J, Tabernero E, Van Cutsem E, A. Ohtsu, J. Albanell, W. Koizumi, M. Peeters. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefitinib (ZD1839). Proc Am Soc Clin Oncol 2003; 22: 191 (A764)
14. Suntharalingam M, Dipetrillo T, Akerman P , Wanebo H, Daly B, Doyle LA, Krasna MJ, Kennedy T, Safran H. Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer. J Clin Oncol 2006; 24 Suppl 18S: 4029
15. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23: 2534-2543
16. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005; 16: 273-278
17. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006; 51: 1371-1379
18. Matsui Y, Inomata M, Tojigamori M, Sonoda K, Shiraishi N, Kitano S. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 2005; 27: 681-685
19. Malumbres M. Preclinical models for cell cycle-targeted therapies. Adv Exp Med Biol 2006; 587: 139-147
20. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24: 1770-1783
21. Yamasaki L, Pagano M. Cell cycle, proteolysis and cancer. Curr Opin Cell Biol 2004; 16: 623-628
22. Blagosklonny MV. Flavopiridol, an inhibitor of transcription: implications, problems and solutions. Cell Cycle 2004; 3: 1537-1542
23. Swanton C. Cell-cycle targeted therapies. Lancet Oncol 2004; 5: 27-36
24. Melillo G, Sausville EA, Cloud K, Lahusen T, Varesio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, down-regulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res 1999; 59: 5433-5437
25. Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002; 50: 465-472
26. Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003; 2: 549-555
27. Senderowicz AM. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog Drug Res 2005; 63: 183-206
28. Kordes U, Krappmann D, Heissmeyer V, Ludwig WD, Scheidereit C. Transcription factor NF-kappaB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia 2000; 14: 399-402
29. Tricot G. New insights into role of microenvironment in multiple myeloma. Lancet 2000; 355: 248-250
30. Kahl BS. Update: gastric MALT lymphoma. Curr Opin Oncol 2003; 15: 347-352
31. Hatakeyama M, Brzozowski T. Pathogenesis of Helicobacter pylori infection. Helicobacter 2006; 11 Suppl 1: 14-20
32. Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol 2006; 12: 2979-2990
33. Zhao XH, Gu SZ, Tian HG, Quan P, Pan BR. Clinical significance of expression of apoptotic signal proteins in gastric carcinoma tissue. World J Gastroenterol 2005; 11: 3846-3849
34. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000; 18: 621-663
35. Sezer O, Vesole DH, Singhal S, Richardson P, Stadtmauer E, Jakob C, Boral AL, Esseltine DL, Mehta J. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 233-235
36. Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC. Bortezomib as an antitumor agent. Curr Pharm Biotechnol 2006; 7: 441-448
37. Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC. Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets 2006; 7: 1341-1347
38. Ocean AJ, Schnoll-Sussman F, Chen X, S. Holloway, N. Matthews, P. Christos, M. Mazumdar, J. Wright, S. Wadler. Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA). Journal of Clinical Oncology 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2006; 24: 14040
39. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89: 1260-1270
40. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263-3266
41. Honda M, Mori M, Ueo H, Sugimachi K, Akiyoshi T. Matrix metalloproteinase-7 expression in gastric carcinoma. Gut 1996; 39: 444-448
42. Sier CF, Kubben FJ, Ganesh S, Heerding MM, Griffioen G, Hanemaaijer R, van Krieken JH, Lamers CB, Verspaget HW. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. Br J Cancer 1996; 74: 413-417
43. Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Niwa H, Tsuneyama K, Takano Y. Expressions of MMP-2, MMP-9 and VEGF are closely linked to growth, invasion, metastasis and angiogenesis of gastric carcinoma. Anticancer Res 2006; 26: 3579-3583
44. Kimata M, Otani Y, Kubota T, Igarashi N, Yokoyama T, Wada N, Yoshimizu N, Fujii M, Kameyama K, Okada Y, Kumai K, Kitajima M. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Jpn J Cancer Res 2002; 93: 834-841
45. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86: 1864-1870
46. Harlozinska A. Progress in molecular mechanisms of tumor metastasis and angiogenesis. Anticancer Res 2005; 25: 3327-3333
47. Chinese source
48. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18: 5356-5362
49. Lazar D, Raica M, Sporea I, Taban S, Goldis A, Cornianu M. Tumor angiogenesis in gastric cancer. Rom J Morphol Embryol 2006; 47: 5-13
50. Whisenant J, Bergsland E. Anti-angiogenic strategies in gastrointestinal malignancies. Curr Treat Options Oncol 2005; 6: 411-121
51. Shah MA, Ramanathan RK, Ilson DH, Levnor A, D'Adamo D, O'Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 2006; 24: 5201-5206
52. Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 2003; 9: 1323-1332
53. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106
54. Hoff PM, Wolff RA, Bogaard K, Waldrum S, Abbruzzese JL. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. Jpn J Clin Oncol 2006; 36: 100-103
55. Tokuyama J, Kubota T, Saikawa Y, Yoshida M, Furukawa T, Otani Y, Kumai K, Kitajima M. Tyrosine kinase inhibitor SU6668 inhibits peritoneal dissemination of gastric cancer via suppression of tumor angiogenesis. Anticancer Res 2005; 25: 17-22
56. McCarty MF, Wey J, Stoeltzing O, Liu W, Fan F, Bucana C, Mansfield PF, Ryan AJ, Ellis LM. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004; 3: 1041-1048
57. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480
58. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338
59. Taddei A, Roche D, Bickmore WA, Almouzni G. The effects of histone deacetylase inhibitors on heterochromatin: implications for anticancer therapy? EMBO Rep 2005; 6: 520-524
60. Ueda T, Takai N, Nishida M, Nasu K, Narahara H. Apicidin, a novel histone deacetylase inhibitor, has profound anti-growth activity in human endometrial and ovarian cancer cells. Int J Mol Med 2007; 19: 301-308
61. Chaudhary N, Ozer H, Huard D, Lightfoot S, Mesiya S. Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab. Dig Dis Sci 2006; 51: 775-778
62. Hopfner M, Baradari V, Huether A, Schofl C, Scherubl H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 2006; 13: 135-149
63. Hopfner M, Sutter AP, Huether A, Baradari V, Scherubl H. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer. World J Gastroenterol 2006; 12: 5635-5643
64. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, Su M, Golec JM, Miller KM. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-267